Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO) will announce its first quarter fiscal year 2021 financial results after market close on May 10. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results and provide corporate updates. Interested participants can join by dialing 866-795-3142, with international callers using 409-937-8908, and using access code 9199306. A live webcast will also be available on their investor relations website, with a replay accessible for two weeks following the call.
Positive
- Scheduled reporting of financial results may indicate transparency and investor engagement.
Negative
- None.
News Market Reaction – ORGO
In the trading session that priced this news, ORGO gained 0.61%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, May 10.
Management will host a conference call at 5:00 p.m. Eastern Time on May 10 to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 9199306. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.
For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 9199306. The webcast will be archived at investors.organogenesis.com.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.